glp-1 substance use disorder receptor agonists are promising but unproven treatments for alcohol and disorders GLP-1 weight-loss drugs show early

Supports Longevity The natural decline of NAD with age can contribute to cellular aging and breakdown of body functions

GLP-1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Zepbound, initially developed for diabetes management, show promising potential in treating psoriasis and psoriatic arthritis (PsA)

Beneficios : Reduce la grasa localizada Elimina la celulitis

And a small clinical trial in people with Alzheimers disease uncovered signs of slowed cognitive decline in those treated with the first generation GLP-1 drug liraglutide, Edisons team reports December 1 in Nature Medicine

These drugs fall within two categories: human GLP-1 backbone agents (that is, albiglutide, dulaglutide, liraglutide and semaglutide) and exendin-4 backbone agents (that is, exenatide, lixisenatide and tirzepatidethe latter activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors) 1

Chen Q, Lai H